FIELD: medicine, cardiology and cardiac surgery.
SUBSTANCE: invention can be used to predict the risk of adverse cardiovascular outcomes within a year after percutaneous coronary interventions with stenting in patients with stable ischemic heart disease. In patients with stable ischemic heart disease, before the planned implantation of a stent, the content of resistin, leptin and testosterone is determined by enzyme immunoassay. Then the risk of developing adverse outcomes is calculated using the following formula: 
where K is the predictive coefficient of adverse cardiovascular events, z is the linear regression coefficient calculated by the following formula: z=(-0.025*X1+0.12*X2+0.03*X3-2.66), where -0.025, 0.12, 0.03 - coefficients; -2.66 - constant value obtained by logistic regression, X1 - serum testosterone level in nmol/ml, X2 - serum resistin level in ng / ml, X3 - serum leptin level in ng/ml. When K is greater than or equal to 0.32, a high risk of adverse cardiovascular events is predicted after percutaneous coronary interventions with stenting. When K is less than 0.32, a low risk of developing adverse cardiovascular events after percutaneous coronary interventions with stenting is predicted.
EFFECT: method makes it possible to predict the risk of developing adverse cardiovascular outcomes after percutaneous coronary interventions with stenting in patients with stable coronary artery disease by determining the serum levels of testosterone, leptin, resistin.
1 cl, 1 dwg, 2 tbl, 2 ex
